Research programme: bispecific antibodies - Alligator Bioscience/Aptevo Therapeutics

Drug Profile

Research programme: bispecific antibodies - Alligator Bioscience/Aptevo Therapeutics

Alternative Names: ADC 1016; ALG.APV 527; ATOR 1016

Latest Information Update: 31 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Alligator Bioscience; Aptevo Therapeutics
  • Class Antineoplastics; Bispecific antibodies
  • Mechanism of Action CD137 antigen antagonists; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 20 Jul 2017 Preclinical development is ongoing in USA
  • 20 Jul 2017 Alligator Bioscience enters into a co-development agreement with Aptevo Therapeutics for development of ALG.APV 527 for solid tumours
  • 21 Jan 2014 Preclinical trials in Cancer in Sweden (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top